ARA-290 (also called cibinetide) is one of the few peptides in the biohacking world that actually came out of serious translational medicine rather than internet lore.
It’s an 11–amino-acid peptide derived from erythropoietin (EPO), but it was engineered very intentionally to avoid stimulating red blood cell production while preserving EPO’s tissue-protective signaling.
That distinction is everything.
Mechanism + translational overview:
https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/
Neuropathy-focused review:
https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/
EPO binds to two different receptor configurations in the body:
The classic EPOR homodimer → stimulates red blood cell production
A heteromeric receptor involving EPOR + CD131 → associated with tissue protection and repair
ARA-290 selectively activates the second pathway. This receptor complex is often referred to in the literature as the Innate Repair Receptor (IRR).
The proposed effects include:
Reduction of inflammatory cytokine signaling
Decreased apoptosis (cell death)
Promotion of cellular repair processes
Receptor discussion:
https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/
EPOR/CD131 context:
https://www.mdpi.com/1422-0067/23/1/55
EMA orphan designation explanation:
https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1191
This isn’t a stimulant. It’s not anabolic. It’s not pushing growth. It’s modulating the body’s response to injury and inflammation.
That makes it potentially powerful — and also more nuanced than people realize.
The most compelling human data comes from sarcoidosis-associated small fiber neuropathy (SFN).
SFN can cause:
Burning pain
Temperature sensitivity
Autonomic dysfunction
Allodynia
Treatment options are usually symptom-based and frankly unsatisfying.
What makes ARA-290 interesting is that some studies measured objective small nerve fiber changes, not just symptom scores.
Randomized, double-blind, small study in sarcoidosis patients with SFN.
It showed safety and symptom improvements over a short course.
Full text:
https://pmc.ncbi.nlm.nih.gov/articles/PMC3563705/
This is the more discussed trial.
Daily subcutaneous cibinetide (1 mg, 4 mg, 8 mg) vs placebo.
Primary endpoint: change in corneal nerve fiber area at 28 days.
That’s important because corneal confocal microscopy allows measurable assessment of small nerve fibers.
PubMed:
https://pubmed.ncbi.nlm.nih.gov/28475703/
Journal page (IOVS):
https://iovs.arvojournals.org/article.aspx?articleid=2625918
ClinicalTrials.gov:
https://clinicaltrials.gov/study/NCT02039687
EU registry results:
https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003016-45/results
What this suggests is a possible disease-modifying effect rather than pure symptom masking.
But — and this matters — these were short-duration studies. We don’t have long-term durability data.
ARA-290 has also been explored in type 2 diabetes with neuropathic symptoms.
Translational discussion:
https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/
PubMed reference:
https://pubmed.ncbi.nlm.nih.gov/25387363/
The theory here is that metabolic inflammation and microvascular dysfunction contribute to nerve injury, and IRR activation may help modulate that response.
Again, promising. Not definitive.
There’s also a phase 2 study in diabetic macular edema, using 4 mg daily for 12 weeks.
Full text:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7408632/
PubMed:
https://pubmed.ncbi.nlm.nih.gov/32674280/
Registry:
https://www.isrctn.com/ISRCTN16962255
This reinforces the idea that cibinetide is being explored in inflammatory and vascular diabetic complications — not as a “biohacker toy,” but as a serious therapeutic candidate.
Let’s clear up the internet mythology.
ARA-290 is not:
A hematocrit booster
A muscle-building peptide
A dopamine enhancer
A fat-loss compound
A narcotic painkiller
It is an immune-modulating, tissue-protective signaling peptide.
That’s a narrower lane than people want it to be.
Here’s what we do not know:
Long-term safety with extended use
Optimal cycling strategy
Durability of nerve regeneration
Effects outside studied populations
Immune consequences with chronic modulation
The neuropathy review explicitly calls for longer-term trials:
https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/
Example of broader preclinical exploration (cisplatin nephrotoxicity model):
https://pubmed.ncbi.nlm.nih.gov/36085231/
Translational medicine is messy. Early signals are encouraging, but they are still early.
Biologically plausible contexts:
Inflammatory small fiber neuropathy
Sarcoidosis-associated neuropathy
Metabolic neuropathy
Conditions where immune-driven tissue stress is central
Less plausible:
Pure mechanical nerve compression
Structural spine pathology
Central sensitization without peripheral damage
Ongoing uncontrolled metabolic or inflammatory drivers
A repair signal cannot outpace ongoing injury.
ARA-290 is one of the more credible peptides in circulation.
It has:
Defined receptor targeting
Human randomized trials
Objective nerve fiber endpoints
A clear mechanistic rationale
It does not have:
Large phase 3 confirmation
Long-term outcome data
Regulatory approval for broad use
So where does that leave it?
In the category of serious translational candidate — not miracle cure, not nonsense.
And honestly, that’s a much more respectable place to be.
Join the Biohacking Peptide Skool Group
Friday’s Telehealth code KELLY for $100 off
Biocare Protein Shake for GLP-1 Users 20% off with Code JUSTLOSEIT
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.